Bausch Health Cos. Inc. (formerly) Valeant Pharmaceuticals is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices, including contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. The company was founded in 1983 and is based in Laval, Canada.
BHC Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for BHC, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Bausch Health Companies Inc ranked in the 11th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Bausch Health Companies Inc, consider:
Interest coverage, a measure of earnings relative to interest payments, is -0.3; that's higher than merely 19.82% of US stocks in the Healthcare sector that have positive free cash flow.
The company's compound free cash flow growth rate over the past 5.69 years comes in at -0.17%; that's greater than merely 9.88% of US stocks we're applying DCF forecasting to.
22% of the company's capital comes from equity, which is greater than just 7.25% of stocks in our cash flow based forecasting set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
RGEN, COO, EW, TEVA, and QGEN can be thought of as valuation peers to BHC, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
LUMIFY® Recognized in the "Superstar" Category for Exceptional Sales and Growth LAVAL, QC, Oct. 1, 2020 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that BASES, a Nielsen Global…
Citron Research founder and activist short seller Andrew Left discussed his latest ideas during an appearance on Benzinga’s PreMarket Prep show Tuesday morning. Left has gained notoriety over the years for successfully betting against Bausch Health Companies Inc (NYSE: BHC ) (formerly Valeant Pharmaceuticals) and a number of fraudulent Chinese stocks, but has also come out positive on a number of stocks he believes are true winners. Short Ideas: One of Left’s current short positions is COVID-19 vaccine play Inovio Pharmaceuticals Inc (NASDAQ: INO ), which Left calls “Pinocchio Pharmaceuticals.” “They were pretty much told by the FDA they can not start Phase 2, so they’re stuck in Phase 1. Now we’re 30 years [with] no product,” Left said. “I don’t know why it’s worth anything more than c...
Bausch Health Companies (BHC) and Eton Pharmaceuticals (ETON) announces that FDA approves Alaway Preservative Free ophthalmic solution antihistamine eye drops as the first OTC preservative-free formulation eye drop."We expect Alaway Preservative Free will be available for purchase in the Spring of 2021 at major retailers in time for the start of allergy...
LAVAL, QC and DEER PARK, Ill., Sept. 25, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), Bausch + Lomb, a leading global eye health business, and Eton Pharmaceuticals, Inc. (NASDAQ: ETON) today announced that the U.S. Food and Drug Administration (FDA)…